tbuckley/cabot-search huggingface dataset:
Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine
Authors: Yanxia Shi, Albert Steppi, Ye Cao, Jianan Wang, Max M. He, Liren Li, Jinfeng Zhang
Journal: Cancer Research (2016)

Asian Americans (AS) have significantly lower incidence and mortality rates of breast cancer than Caucasian Americans (CA). Although this racial disparity has been documented, the underlying pathogenetic factors explaining it are obscure. We addressed this issue by an integrative genomics approach to compare mRNA expression between AS and CA cases of breast cancer. RNA-seq data from the Cancer Genome Atlas showed that mRNA expression revealed significant differences at gene and pathway levels. Increased susceptibility and severity in CA patients were likely the result of synergistic environmental and genetic risk factors, with arachidonic acid metabolism and PPAR signaling pathways implicated in linking environmental and genetic factors. An analysis that also added eQTL data from the Genotype-Tissue Expression Project and SNP data from the 1,000 Genomes Project identified several SNPs associated with differentially expressed genes. Overall, the associations we identified may enable a more focused study of genotypic differences that may help explain the disparity in breast cancer incidence and mortality rates in CA and AS populations and inform precision medicine. Cancer Res; 77(2); 423-33. ©2016 AACR.
AB0332 Golimumab Efficacy in Rheumatoid Arthritis after Conventional and Biological Treatment: Data from The Italian Lorhen Registry
Authors: V. Grosso, R. Gorla, P. Sarzi-Puttini, F. Atzeni, R. Pellerito, E. Fusaro, G. Paolazzi, P.A. Rocchetta, E.G. Favalli, A. Marchesoni, R. Caporali
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The efficacy of Golimumab (GLM) treatment in rheumatoid arthritis (RA) has been widely documented in clinical trials. Data are still needed to assess its efficacy and tolerability in everyday clinical practice. <h3>Objectives</h3> To assess the efficacy of the treatment with GLM in RA previously treated with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) or biological DMARDs (bDMARDs) from a multicentric observational cohort (the LORHEN Registry). <h3>Methods</h3> All patients with a diagnosis of RA in the LORHEN database who started GLM from october 2010 up to september 2015, with at least one reported visit, were included. We reviewed the data regarding the first 24 months of treatment, focusing on clinical efficacy. The efficacy of GLM was assessed with DAS28, DAS28(CRP), SDAI and EULAR response criteria. We executed intention-to-treat (ITT) and per-protocol analysis (PP). We repeated the analysis for the subgroups of patients who received GLM as first or second bDMARD. <h3>Results</h3> We retrieved the data regarding 180 patients, with a mean (sd) age of 54,57 (13,62) years and a mean (sd) disease duration of 9,52 (9,32) years. Methotrexate was the concomitant csDMARD for 123 (68,3%) patients, while leflunomide, sulfasalazine and cyclosporine were given to 13 (7,2%), 5 (2,8%) and 4 (2,2%) patients respectively. 35 (19,4%) patients were treated with GLM monotherapy. 137 (76,1%) and 5 (2,8%) patients were given low dose (≤10mg prednisone equivalent a day) and medium dose (≥10 and ≤25) corticosteroid at baseline, with following tapering. A total of 79 patients stopped the treatment with GLM due to inefficacy or adverse events before 24 months of treatment. With the ITT design 55 (30,6%) and 44 (24,4%) patients achieved good or moderate EULAR response respectively at 6 months. The mean (sd) DAS28, DAS28(CRP) and SDAI progressively reduced, reaching 2,61 (1,11), 2,41 (0,72) and 4,62 (3,80) respectively at 24 months. Within the PP scenario, 32 (66,7%) and 9 (18,8%) patients reached and maintained good or moderate EULAR response respectively to the end of the follow-up. The clinical response to GLM therapy resulted slightly reduced when given as a second line bDMARD treatment, but the data did not met statistical significance. <h3>Conclusions</h3> GLM is effective in treating RA in everyday clinical practice. The efficacy increases significantly over the first 6 months and slightly during the following 18 months. Interestingly enough, patients treated with GLM after a first bDMARD can still achieve low disease activity and clinical remission, with an overall efficacy of the treatment not statistically different to the first line. <h3>Disclosure of Interest</h3> None declared
A Large Mennonite Family with a Novel K570N TERT Gene Mutation: Association with a Clinical Spectrum of Bone Marrow Failure, Acute Myeloid Leukemia, and Acute Liver Failure.
Authors: Joshua A. Regal, Rodrigo T. Calado, Aarthi Shenoy, Peter M. Lansdorp, Neal S. Young
Journal: Blood (2006)
A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin’s Lymphoma.
Authors: Ranjana H. Advani, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Andres Forero-Torres, Kate L. Harrop, Karen T. Baumgartner, Michael McDonald, Jonathan G. Drachman
Journal: Blood (2005)
Alternative Splicing of hTERT Exon 7 in AML: Biological Fuction and Prognostic Significance
Authors: Paolo Bernasconi, Barbara Rocca, Celeste Calvello, Catherine Klersy, Marina Boni, Rita Zappatore, Irene Dambruoso, Paola Maria Cavigliano, Ilaria Giardini, Marilena Caresana, Antonella Orlando, Mirko Farina
Journal: Blood (2014)
Operationalizing Network Theory for Ecosystem Service Assessments
Authors: Laura E. Dee, Stefano Allesina, Aletta Bonn, Anna Eklöf, Steven D. Gaines, Jes Hines, Ute Jacob, Eve McDonald-Madden, Hugh Possingham, Matthias Schröter, Ross M. Thompson
Journal: Trends in Ecology & Evolution (2016)
FRI0459 Longitudinal Evolvement of PASDAS and CPDAI and Its Associations with Patients Characteristics and Treatment in Incident Psoriatic Arthritis: Results from The Depar Study
Authors: K. Wervers, M. Vis, I. Tchetverikov, A.H. Gerards, M.R. Kok, C.W.Y. Appels, W.L. van der Graaff, J.H.L.M. van Groenendael, L.-A. Korswagen, J. Veris, J.M.W. Hazes, J.J. Luime
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic Arthritis (PsA) is a multi-features disease requiring disease activity measures that capture not only joint disease, such as the Composite Psoriatic Disease Activity Index (CPDAI) and the Psoriatic Arthritis Disease Activity Score (PASDAS). Although both are well validated in clinical trials, little data exists on their evolvement in daily clinical care. <h3>Objectives</h3> to describe the longitudinal evolvement of CPDAI and PASDAS and its associations with demography, disease, and DMARDs. <h3>Methods</h3> Newly diagnosed consecutive PsA patients were recruited in 8 hospitals in the Netherlands from August 2013 to November 2015. Demographic and disease characteristics were registered. Data was analysed in the first 3 months by linear regression and over 12 months using linear mixed model with random intercept for CPDAI (0–15) and PASDAS (0–10) <h3>Results</h3> In November 2015 281 patients had had a baseline assessment, of which 234, 198, 157 and 129 had had resp. a 3, 6, 9 and 12 month assessment. The mean age was 50.6 (SD 13.6) and 50.5% were male. In terms of arthritis subtypes, 56 (20%) had monoarthritis, 108 (39%) oligoarthritis, 80 (29%) polyarthritis and 35 (12%) were diagnosed with axial disease, dactylitis or enthesitis only. PASDAS evolved from a mean of 4.0 points (SD 1.2, n=174) at baseline, to 3.3 (SD 1.1, n=160) at 3 months, and 2.6 (SD 1.1, n=94) at 12 months. CPDAI evolved from 5.5 (SD 2.1, n=229), to 4.4 (SD 2.0, n=213) to 2.97 (SD 1.8, n=113) resp. Associations and their course over time are described in table 1. In summary: MTX had a lowering effect on both the CPDAI and PASDAS in the multivariate analysis, while baseline scores and disease duration had a raising effect. Higher baseline PASDAS and CPDAI values in the multivariate analysis were associated with being female, the presence of oligo- or polyarthritis and tender enthesis, for CPDAI also with the presence of morning stiffness. Similar results were observed in the 3-months linear regression. <h3>Conclusions</h3> PASDAS and CPDAI decrease over time associated with the use of Methotrexate, while higher baseline values and longer disease duration affected this negatively. <h3>Disclosure of Interest</h3> None declared
The Association of 14-3-3ζ and Filamin A with the Central Cytoplasmic Domain of GPIbα Involves in Regulation of the Von Willebrand Factor Binding and Signaling Functions of Platelet Glycoprotein Ib-IX.
Authors: Weilin Zhang, Yanhong Yuan, Lili Zhao, Yi Liao, Changgeng Ruan, Kesheng Dai
Journal: Blood (2009)
Similar Incidence of Severe Acute Gvhd and Less Extensive Chronic Gvhd in PBSCT from Unmanipulated Haploidentical Donor Compared with That from Matched Sibling Donor for Patients with Hematologic Malignancies
Authors: Honghua Li, Wenrong Huang, Chunji Gao, Liping Dou, Fei Li, Quanshun Wang, Lili Wang, Li Yu, Dai-Hong Liu
Journal: Blood (2015)
Expression of Tropomodulin1 (Tmod1) in the Heart Rescues Embryonic Lethality of Tmod1 Null Mice and Results in a Mild Hemolytic Anemia Due to Absence of Tmod1 in Red Blood Cells.
Authors: Velia M. Fowler, Jeannette Moyer, Roberta Nowak, Kimberly Fritz-Six, Carmela Ferreira-Mota, Mark A. Sussman
Journal: Blood (2005)
THU0302 Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes:
Authors: M.Y. Md Yusof, D. Shaw, A. Rawstron, P. Emery, E.M. Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rituximab is effective for SLE in open label series however level of clinical response varies and was not superior to standard of care in randomised trials. We previously showed that clinical response was associated with the depth of initial B cell depletion and relapse was associated with early plasmablast repopulation [1]. <h3>Objectives</h3> To validate B cell depletion as a predictor of response to rituximab in SLE as a basis to develop more effective B cell targeted therapy. <h3>Methods</h3> The published discovery cohort included 38 renal and extra-renal lupus patients. A validation cohort of 46 new patients was recruited. All patients received an initial cycle of 2 infusions of 1000mg rituximab, each preceded by 100mg methylprednisolone. Rituximab was repeated on clinical relapse. Concomitant therapy with cyclophosphamide was not used. Oral immunosuppressants were continued if used at baseline. Oral prednisolone doses varied. B cell depletion using a protocol optimized to detect low numbers of B cell subsets and plasmablasts was measured at baseline, after both infusions of rituximab (6 weeks) and at early B cell repopulation (6 months). Complete depletion was defined as total B cell count &lt;0.0001x10<sup>9</sup>/L <h3>Results</h3> Depletion and response data were available for 84/100 patients. Overall complete depletion rate was 54%. Incomplete depletion was predicted at baseline by low complement C4 (p=0.044) but not baseline BILAG score or immunosuppressant use. In original cohort there was a significant association between plasmablast repopulation (&gt;0.0008x10<sup>9</sup>/L) and time to relapse &lt;18 months (p=0.024). Follow up for relapse was limited to 22/36 responders in the validation cohort at the time of analysis, with a trend to the same association (p=0.119). <h3>Conclusions</h3> We have validated depth of B cell depletion as a predictor of response to rituximab in SLE. Clinical trials using more intensive rituximab treatment regimens, or alternative CD20 molecules are likely to increase clinical response rates to B cell depletion in clinical trials. B cell subsets should be monitored in the routine care of SLE patients receiving rituximab and repeat infusions considered if early depletion is incomplete or plasmablast repopulation is detected at 6 months. <h3>References</h3> Vital EM et al. A&amp;R 2012. <h3>Disclosure of Interest</h3> M. Y. Md Yusof: None declared, D. Shaw: None declared, A. Rawstron: None declared, P. Emery Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Consultant for: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, E. M. Vital: None declared
Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development
Authors: George L. Chen, Sally Arai, Mary E.D. Flowers, Joanne M Otani, Marc Coram, Alex McMillan, Judith A Shizuru, Laura Johnston, David Miklos
Journal: Blood (2010)
Monitoring of Bone Marrow Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation – Evaluation of a qPCR Based Chimerism Assay
Authors: Roland Reibke, Andrea Dick, Max Hubmann, Eva Hoster, Reinhard Henschler, Wolfgang Hiddemann, Karsten Spiekermann, Johanna Tischer
Journal: Blood (2014)
Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)
Authors: Peter Rhein, Richard Ratei, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N Dworzak, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew
Journal: Blood (2008)
Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity
Authors: Torsten Kucharzik, Bianca M. Wittig, Ulf Helwig, Norbert Börner, Alexander Rössler, Stefan Rath, Christian Maaser, Axel Naumann, Gregor Pelster, Jörg Spengler, Carsten Büning, Enno Gentz, Harald Matthes, Dieter Nürnberg, Adelheid Jung, Jochen Maul, Daniel C. Baumgart, Deike Strobel, Gabriele Manok, Matthias Breidert, Michael Scheurlen, Andreas Stallmach, Uwe Will, Thomas Krause, Rolf-Achim Krüger, Niels Teich, Ingolf Schiefke, Annette Krummenerl, Klaus Fellermann, Rüdiger Kilian, Torsten Kucharzik, Christian Maaser, Ulf Helwig, Volker Meister, Stefan Mielck, Diether Ludwig, Norbert Börner, Stefan Schanz, Robert Kihn, Robert Manfred Hoffmann, Barbara Lanyi, Robert Ehehalt, Burghard Wilborn, Franz Ludwig Dumoulin, Wolfgang Mohl, Andreas Lügering, Thomas Krummenerl, Jan Heidemann, Matthias Pichler, Hans Allescher, Frank Meyer-Hilse, Gerd-Rüdiger Franke, Oliver Bachmann, Martin Fähndrich
Journal: Clinical Gastroenterology and Hepatology (2016)
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).
Authors: Meletios A. Dimopoulos, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, Argiris Symeonidis, Eurydiki Michalis, Panayiotis Repoussis, Costas Tsatalas, Michalis Michael, Anastasia Sioni, Ekaterini Stefanoudaki, Zafiris Kartasis, Michael Voulgarelis, Sosana Delimpasi, Efstathios Kastritis, Maria Gavriatopoulou, Efstathios Koulieris, Dimitra Gika, Paraskevi Roussou, Nikolaos Anagnostopoulos, Evangelos Terpos, Theofanis Economopoulos, Konstantinos Zervas
Journal: Blood (2009)
A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve
Authors: Emanuele Barbato, Gabor G. Toth, Nils P. Johnson, Nico H.J. Pijls, William F. Fearon, Pim A.L. Tonino, Nick Curzen, Zsolt Piroth, Gilles Rioufol, Peter Jüni, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2016)
Modulation of Graft-Versus-Host Disease Induced by Central Memory Suicide Gene Modified Human T Lymphocytes.
Authors: Bondanza Attilio, Valtolina Veronica, Magnani Zulma, La Seta Catamancio Simona, Benati Claudia, Toma Salvatore, Traversari Catia, Radrizzani Marina, Bonyhadi Mark, Ciceri Fabio, Bordignon Claudio, Bonini Chiara
Journal: Blood (2004)
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
Authors: Maowen Ba, Min Kong, Xiaofeng Li, Kok Pin Ng, Pedro Rosa-Neto, Serge Gauthier
Journal: Translational Neurodegeneration (2016)

Amyloid plaques are pathological hallmarks of Alzheimer's Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1–42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers.
Molecular weight determination of a newly synthesized guanidinylated disulfide-containing poly(amido amine) by gel permeation chromatography
Authors: Haonan Xing, Mei Lu, Lei Xian, Jinmin Zhang, Tianzhi Yang, Li Yang, Pingtian Ding
Journal: Asian Journal of Pharmaceutical Sciences (2016)

A cationic gene delivery vector, guanidinylated disulfide-containing poly(amido amine) (CAR-CBA), was synthesized by Michael addition reaction between N,N′-cystaminebisacrylamide (CBA) and guanidine hydrochloride (CAR). Gel permeation chromatography (GPC) was used to evaluate the molecular weight of synthesized CAR-CBA. Polyethyleneimine (PEI) with molecular weight of 25 kDa was adopted as a reference, and polyethylene glycols (PEG) with different molecular weights were used to establish a standard curve for determining the molecular weight of CAR-CBA. The effects of two critical factors, namely columns and eluents, on the molecular weight measurement of CAR-CBA were investigated to optimize the GPC quantitative method. The results showed that Ultrahydrogel columns (120, 250) and HAc–NaAc (0.5 M, pH 4.5) buffer solution were the optimal column and GPC eluent, respectively. The molecular weight of the synthesized CAR-CBA was analyzed by the optimized GPC method and determined to be 24.66 kDa.
Translational Regulation of Gene Expression by the NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma: A Global Evaluation of Differentially Recruited mRNA’s to Polyribosomes.
Authors: Kotaro Funato, Naznin Haq, Yezhou Sun, Jin Chen, Greg Khitrov, Weijia Zhang, David W. Sternberg
Journal: Blood (2006)
Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?
Authors: Jin S. Im, Rima M Saliba, Susan C Abraham, William Ross, Gabriela Rondon, Asif Rashid, Elizabeth J. Shpall, Uday R. Popat, Muzaffar Qazilbash, Chitra M. Hosing, Betul Oran, Nina Shah, Richard E. Champlin, Amin M. Alousi
Journal: Blood (2015)
SAT0457 A Markedly Higher Proportion of The Variance in Hip Arthroplasty than in Knee Arthroplasty Can Be Explained by Heritability
Authors: K. Magnusson, E. Ystrøm, R. Ørstavik, T. Nilsen, C. Nielsen, Ó.A. Steingrímsdόttir, P. Ferreira, K. Scurrah, A.M. Fenstad, O. Furnes, K.B. Hagen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoarthritis (OA) may lead to costly total joint replacements (TJR) of the knee and hip joints. To what extent TJR due to OA at the different joint sites is caused by hereditary or environmental factors is unknown. This information may aid in determining whether hip or knee arthroplasties are possible to prevent. <h3>Objectives</h3> To explore the genetic contribution to TJR due to hip and knee OA for women, men, young and elderly using a twin registry design. <h3>Methods</h3> The study is a prospective cohort study based on a linkage of the Norwegian Twin Registry and the Norwegian Arthroplasty Registry using the National ID number in 2014. The presence of a TJR due to hip and knee OA has been registered for &gt;95% of the population from 1987 (hip) and 1994 (knee). We first calculated prevalence estimates across twin groups (same sex twin pairs born 1915–1960), and subsequently examined the relative contribution of genetic factors (heritability), shared and non-shared environmental factors, applying the classical twin model. <h3>Results</h3> The sample comprised 9029 complete pairs of which 3803 monozygotic (MZ) and 5226 dizygotic (DZ) pairs (54% females and mean (SD) age 71.5 (12.7) for both zygosity groups). The prevalence for having a TJR was similar across zygosity with 3.6% (n=614) for the hip and 1.8% (n=317) for the knee joint. In total 50 MZ/30 DZ and 10 MZ/5 DZ twin pairs were concordant for hip and knee arthroplasty, respectively. Concordances and polychoric correlations were higher for MZ twins than DZ twins both for hip and knee artrhoplasty in all age and sex strata (Table). A model including only genetic and environmental factors unique to each twin in a pair provided the best fit. The heritability for TJR largely depended on OA site. A markedly higher proportion of the variance in hip arthroplasty than in knee arthroplasty could be explained by heritable factors (Table). The variance in TJR due to knee OA was to a greater extent explained by environmental factors unique to each twin (Table). A significant gene-age interaction could be observed for the knee joint with a high observed heritability for twins below median age (68 years) changing to a low heritability after median age. Heritability estimates for TJR due to hip OA remained high and stable across age and sex groups, although a slightly higher heritability could be observed for men (Table). <h3>Conclusions</h3> The heritability of TJR due to OA depends on joint site. Preventive interventions may have a greater potential for knee arthroplasty than hip arthroplasty, particularly for knee arthroplasty at old age. The difference in heritability across age and sex groups for TJR due to knee OA should be further studied due to a low number of concordant pairs. <h3>Disclosure of Interest</h3> None declared
Bone Remodeling: Theranostic Bioabsorbable Bone Fixation Plate with Drug-Layered Double Hydroxide Nanohybrids (Adv. Healthcare Mater. 21/2016)
Authors: Myung Hun Kim, Woojune Hur, Goeun Choi, Hye Sook Min, Tae Hyun Choi, Young Bin Choy, Jin-Ho Choy
Journal: Advanced Healthcare Materials (2016)

Choy and his team demonstrate a novel strategy for precise theranostic bone repair on page 2765. A theranostic layer is made of a composite of risedronate-layer double hydroxide (RSLDH) nanohybrids and biodegradable polymer (poly(lactic-co-glycolic acid)), in which both radiopacity (diagnostic) and risedronate delivery (therapeutic) could be controlled upon changing the layer property. A combined entity of the theranostic layer and biodegradable, orthopedic fixation device allows for post-surgery diagnosis and expedited bone repair in in vivo cranial defect animal models.
Prognostic Implications of Oligoclonal Bands in Patients with Multiple Myeloma:Its Development per Se did Not Confer the Prologation of Survival
Authors: Manabu Fujisawa, Yasuhito Suehara, Keisuke Seike, Kota Fukumoto, Masafumi Fukaya, Hiroki Sugihara, Masami Takeuchi, Kosei Matsue
Journal: Blood (2014)
Serum-Soluble Tumor Necrosis Factor Receptor 2 (sTNF-R2) Level Determines Clinical Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma.
Authors: Hisashi Tsurumi, Naoe Goto, Masao Takemura, Takeshi Hara, Michio Sawada, Toshiki Yamada, Senji Kasahara, Nobuhiro Kanemura, Takeshi Takahashi, Masami Oyama, Eiichi Tomita, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2004)
Activated T Cells (ATC) Armed with Anti-CD3 X Anti-Her2/Neu Bispecific Antibody (Her2Bi) Is a Potent Immunomodulator
Authors: Oxana Norkina, Archana Thakur, Maxim Norkin, Elyse Paul, Zaid Al-Kadhimi, Lawrence G. Lum
Journal: Blood (2008)
Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,
Authors: Saad Usmani, Sarah Waheed, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, Yazan Alsayed, Antje Hoering, John Crowley, Bart Barlogie
Journal: Blood (2011)